Latest Period
Q1 2026
Security Snapshot
Cyclerion Therapeutics, Inc. - Common Stock, no par value (CYCN) Institutional Ownership
CUSIP: 23255M204
13F Institutional Holders and Ownership History from Q1 2023 to Q1 2026
Institutions Reporting
17
Shares (Excl. Options)
161,922
Price
$1.55
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, no par value
- Symbol
- CYCN on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 161,922
- Total 13F value
- $249,026
- Portfolio coverage rank
- 0%
- Share change
- -134,333
- Value change
- -$153,367
- Number of holders
- 17
- Shares outstanding
- 3,367,000
- SEC-reported price per share
- $3.21
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- CYCN - Cyclerion Therapeutics, Inc. - Common Stock, no par value is tracked under CUSIP 23255M204.
- 17 institutions reported positions in Q1 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 18 to 17 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $376,255 to $249,026.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 17 institutions filings for Q1 2026.
Security key
23255M204
Latest holder period
Q1 2026
13F holders
17
13D/G owners
5
CIK / CUSIP context first
Open Q1 2026 holders
CYCN full holder history
Cyclerion Therapeutics, Inc. SEC filings
Cyclerion Therapeutics, Inc. company facts
Cyclerion Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 23255M204:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
CYCN
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Hecht Peter M | 28% | $3,803,918 | 1,028,086 | Peter M. Hecht | 25 Mar 2025 | |||
| J. WOOD CAPITAL ADVISORS LLC | 5.4% | $496,363 | 181,818 | J. Wood Capital Advisors LLC | 25 Mar 2025 | |||
| TYNDALL CAPITAL PARTNERS L P | 4.8% | -6% | $487,287 | -$30,113 | 155,187 | -5.8% | Tyndall Capital Partners, L.P. | 30 Jun 2025 |
| American Endowment Foundation | 4.9% | $492,196 | 133,026 | American Endowment Foundation | 31 Dec 2024 | |||
| FMR LLC | 0.2% | $17,538 | 4,740 | FMR LLC | 31 Dec 2024 |
As of 31 Mar 2026, 17 institutional investors reported holding 161,922 shares of Cyclerion Therapeutics, Inc. - Common Stock, no par value (CYCN). This represents 4.8% of the company’s total 3,367,000 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
13
Latest
Q1 2026
Rows shown
1-13 of 13
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 161,922 | $249,026 | -$153,367 | $1.55 | 17 |
| 2025 Q4 | 296,254 | $376,255 | +$3,325 | $1.27 | 18 |
| 2025 Q3 | 258,836 | $595,353 | -$333,887 | $2.30 | 17 |
| 2025 Q2 | 362,816 | $1,055,824 | -$30,767 | $2.91 | 17 |
| 2025 Q1 | 373,392 | $931,696 | -$29,342 | $2.50 | 18 |
| 2024 Q4 | 382,073 | $1,230,314 | -$1,793,165 | $3.22 | 19 |
| 2024 Q3 | 1,042,639 | $2,696,608 | -$289,148 | $2.59 | 15 |
| 2024 Q2 | 1,051,710 | $2,411,691 | -$42,676 | $2.30 | 17 |
| 2024 Q1 | 1,070,254 | $3,424,719 | +$2,411 | $3.20 | 15 |
| 2023 Q4 | 1,069,490 | $3,583,217 | -$8,652 | $3.35 | 15 |
| 2023 Q3 | 1,072,275 | $3,658,805 | +$244,093 | $3.42 | 17 |
| 2023 Q2 | 995,440 | $4,096,493 | +$4,096,489 | $4.12 | 17 |
| 2023 Q1 | 10 | $4 | +$4 | $0.40 | 1 |